Multi-Stakeholder Study Reveals That Clinical Research Participation Leads to Higher Patient Engagement, Reduced Cost of Care
Quintiles , the world’s largest provider of product development and integrated healthcare services, today published new research that reveals high levels of patient satisfaction and engagement in clinical research. Based on a survey of U.S. clinical research patients, all of the respondents agreed that clinical research participation reduced their overall cost of healthcare and improved their interest/involvement in their overall health.
In addition, 95 percent of survey participants said that participating in clinical research positively impacted their overall quality of care.
“These findings illustrate the value of integrating clinical research into the traditional continuum of care,” said Jeanne Hecht, senior vice president, Site & Patient Networks at Quintiles. “It is imperative that we continue to prioritize and support the patient and physician experience in clinical research. Coupled with high-quality processes, this support enables the right physician to connect the right patient to the right trial.”
In this survey, participants were patients with type II diabetes involved in an ongoing diabetes clinical trial. The clinical trial is scheduled to continue for four years, and participants will be surveyed annually until the conclusion of the clinical trial.
To learn more about this research, download Quintiles’ new paper, “Clinical Research Participation as a Care Option .” The paper is co-authored by experts from the global biopharmaceutical and research industries.
This research will be discussed at Quintiles’ inaugural Site Vision Forum on October 29-30, 2015 in Charlotte, N.C. The interactive event will bring together sites to discuss key trends and identify areas for increased collaboration and support. Quintiles will host a second Site Vision Forum in Europe this December.
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com .
Click here to subscribe to Mobile Alerts for Quintiles.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PHILIP-MORRIS-INTL21.7.2018 20:21 | pressemeddelelse
Philip Morris International Announces Non-Executive Board Chairman Louis Camilleri to Assume CEO Role at Ferrari S.p.A.
LOXAM20.7.2018 16:53 | pressemeddelelse
Loxam Announces a Conditional Agreement to Acquire UK Platforms
SCHLUMBERGER-LIMITED20.7.2018 13:02 | pressemeddelelse
Schlumberger Announces Second-Quarter 2018 Results
FL-H.I.G.-CAPITAL19.7.2018 21:52 | pressemeddelelse
H.I.G. Capital Announces the Sale of KidsFoundation
SIG-COMBIBLOC-GROUP19.7.2018 18:03 | pressemeddelelse
SIG Combibloc Group Holdings S.à r.l.: 2018 Second Quarter Results
FL-NEORIS19.7.2018 17:34 | pressemeddelelse
NEORIS Announces Creation of Innovation Labs Worldwide to Create a Smarter Future
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum